Immunovant (IMVT) Gains from Investment Securities (2019 - 2026)
Immunovant (IMVT) reported Gains from Investment Securities of -$1.3 million for Q1 2026, down 116.82% on a YoY basis from $7.7 million in Q1 2025, and down 3523.68% quarter-over-quarter from $38000.0 in Q4 2025.
Immunovant (IMVT) Gains from Investment Securities (2019 - 2026) Analysis & Trends
Immunovant has reported Gains from Investment Securities for 7 years, with the latest figure at -$1.3 million in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities fell 116.82% year-over-year to -$1.3 million; the trailing twelve-month figure through Mar 2026 stood at -$69000.0 (down 100.89% YoY), and the FY2026 full-year result was -$69000.0, down 100.89% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at -$1.3 million, down from $38000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $8.1 million in Q3 2024, with the low at -$8.1 million in Q4 2024.
- Historically, Gains from Investment Securities has averaged $876111.1 across 4 years, with a median of $91000.0 in 2024.
- Annual changes were most pronounced in 2025 — Gains from Investment Securities jumped 8401.1% — and 2026, when it slumped 116.82%.
- Immunovant's Gains from Investment Securities stood at $127000.0 in 2022, then plunged by 6455.12% to -$8.1 million in 2024, then jumped by 100.47% to $38000.0 in 2025, then slumped by 3523.68% to -$1.3 million in 2026.
- The last three Gains from Investment Securities figures came in at -$1.3 million (Q1 2026), $38000.0 (Q4 2025), and -$167000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Immunovant | 5.71 Bn | 5.71 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.30 Mn |
| Mar 31, 2026 | -1.30 Mn |
| Dec 31, 2025 | 38,000.00 |
| Dec 31, 2025 | 38,000.00 |
| Sep 30, 2025 | -167,000.00 |
| Sep 30, 2025 | -167,000.00 |
| Jun 30, 2025 | 1.36 Mn |
| Jun 30, 2025 | 1.36 Mn |
| Mar 31, 2025 | 7.74 Mn |
| Mar 31, 2025 | 7.74 Mn |
| Dec 31, 2024 | -8.07 Mn |
| Dec 31, 2024 | -8.07 Mn |
| Sep 30, 2024 | 8.07 Mn |
| Sep 30, 2024 | 8.07 Mn |
| Mar 31, 2024 | 91,000.00 |
| Mar 31, 2024 | 91,000.00 |
| Mar 31, 2022 | 127,000.00 |
| Mar 31, 2022 | 127,000.00 |
| Dec 31, 2021 | 740,000.00 |
| Dec 31, 2021 | 740,000.00 |